Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.75 |
| ▸ | STK10 | O94804 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | RET | P07949 | 2/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.75 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | CSF1R | P07333 | 1/20 | 0.75 |
| ▸ | HCK | P08631 | 1/20 | 0.75 |
| ▸ | KIT | P10721 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227092 | 0.92 | KDR (0.73) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL14111459 | 0.92 | KDR (0.62) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1226645 | 0.90 | KDR (0.76) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227392 | 0.88 | KDR (0.75) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227552 | 0.87 | KDR (0.77) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL3451491 | 0.86 | KDR (0.78) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL14140810 | 0.86 | KDR (0.77) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227548 | 0.86 | KDR (0.77) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227112 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL29354510 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980605-B2 | Ketoreductases and uses thereof | CODEXIS, INC. (US) | 2015-03-17 | — | — | US | claimed |
| US-20130196408-A1 | KETOREDUCTASES AND USES THEREOF | CODEXIS, INC. (US) | 2013-08-01 | — | — | US | claimed |
| EP-2115130-B1 | KETOREDUCTASES AND USES THEREOF | CODEXIS INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-7820421-B2 | capable of reducing or converting the compound I-[4-(4-fluoro2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-one to the corresponding product (R) 1-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2- | CODEXIS, INC. (US) | 2010-10-26 | — | — | US | claimed |
| EP-2115130-A1 | KETOREDUCTASES AND USES THEREOF | Codexis, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| US-20080318295-A1 | capable of reducing or converting the compound I-[4-(4-fluoro2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-one to the corresponding product (R) 1-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2- | CODEXIS, INC. (US) | 2008-12-25 | — | — | US | claimed |
| WO-2008103248-A1 | KETOREDUCTASES AND USES THEREOF | CODEXIS, INC. (US) | 2008-08-28 | — | — | WO | claimed |
| US-8980605-B2 | Ketoreductases and uses thereof | CODEXIS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980605-B2 | Ketoreductases and uses thereof | CODEXIS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130196408-A1 | KETOREDUCTASES AND USES THEREOF | CODEXIS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196408-A1 | KETOREDUCTASES AND USES THEREOF | CODEXIS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8415127-B2 | Ketoreductases and uses thereof | CODEXIS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415127-B2 | Ketoreductases and uses thereof | CODEXIS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-7393667-B2 | Stereoselective reduction process for the preparation of pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060286646-A1 | STEREOSELECTIVE REDUCTION PROCESS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | US | disclosed |
| US-20050124621-A1 | Novel inhibitors of kinases | BHIDE RAJEEV S (US) | 2005-06-09 | — | — | US | disclosed |
| US-6869952-B2 | Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040072832-A1 | Novel inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318295-A1 | capable of reducing or converting the compound I-[4-(4-fluoro2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2-one to the corresponding product (R) 1-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-propan-2- | AKR1A1, TKT, AKR1B1 | KDR 1475/4885CYP3A4 335/4885FGFR1 2140/4885 |
| US-20060286646-A1 | STEREOSELECTIVE REDUCTION PROCESS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS | ADH1C, ADH5, ADH1A | KDR 4188/4885CYP3A4 76/4885FGFR1 2346/4885 |
| US-20040072832-A1 | Novel inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 6/4885CYP3A4 2931/4885FGFR1 1/4885 |
| US-20050124621-A1 | Novel inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 7/4885CYP3A4 3014/4885FGFR1 1/4885 |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | FGFR1, FLT1, FGFR2 | KDR 9/4885CYP3A4 2215/4885FGFR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.